intracellular signals and mediates the release of proinflammatory cytokines such as TNF-α in macro phages (9) . Moreover, HMGB1 directly induces synovial cell proliferation and osteoclastogenesis, leading to the destruction of cartilage and bone (12) (13) (14) . Thus, HMGB1 plays a critical role in the pathogenesis of RA and may become a putative target for successful RA treatment.
RAGE is composed of (a) an N-terminal extracellular domain with a ligandengaging V-region-like domain essential for binding with HMGB1 and two C-region-like domains; (b) a single pass transmembrane domain; and (c) a C-terminal highly charged, short cytoplasmic domain essential for signal transduction (15) (16) (17) . A soluble RAGE (sRAGE), a truncated form of the receptor, is composed of only the extracellular ligand-binding domain lacking the cytosolic and transmembrane domains. In humans, sRAGE is produced by alternative splicing of RAGE mRNA (18, 19) . Yonekura et al. (20) identified a naturally occurring sRAGE lacking transmembrane and intracellular domains in humans and named it endogenous secretory RAGE (esRAGE). This soluble form of the receptor is a C-terminally truncated type and has a V-domain essential for binding with the ligand such as HMGB1. Therefore, esRAGE has the same ligand binding specificity, competes with cell-bound RAGE for ligand binding and functions as a decoy abrogating cellular activation (20, 21) .
An innovative drug delivery system by using acidic oligopeptides to target bone was proposed and investigated experimentally and clinically (22) (23) (24) . This unique approach is based on the physical properties of several noncollagenous bone proteins that have repetitive sequences of acidic amino acids (L-aspartic acid [L-Asp] or L-glutamine [L-Glu] ) and bind to hydroxyapatite (HA) (25, 26) . It was indicated that the antibiotics fluoroquinolones, tagged with an acidic oligopeptide, were successfully targeted to bone and could be effective in treating osteomyelitis if the appropriate dose was given (24) . We and other groups have applied this bonetargeting system to large molecules, namely, enzymes (tissue-nonspecific alkaline phosphatase, β-glucuronidase and N-acetylgalactosamine-6-sulfate sulfatase), showing that the tagged enzymes were delivered more efficiently to bone and that the clinical and pathological improvement in bone was observed in murine models of hypophosphatasia, mucopolysaccharidosis VII and mucopolysaccharidosis IVA, respectively (27) (28) (29) (30) . The clinical trial for the patients with hypophosphatasia is now in progress with a favorable clinical consequence rescuing the devastating skeletal bone disease (31) .
In this study, we applied and developed the bone-targeting drug delivery system for RA by tagging the acidic oligopeptide to esRAGE and evaluated the in vivo therapeutic effect of targeted esRAGE on the RA murine model.
MATERIALS AND METHODS

Mice and Reagents
Six-week-old male DBA/1J mice were purchased from Japan SLC (Hamamatsu, Japan). All mouse experiments were performed in accordance with the guidelines of the Committee on Animal Experiments at Hokuriku University.
Human lung total RNA was obtained from Clontech (Mountain View, CA, USA To produce acidic oligopeptide-tagged esRAGE, a stretch of 6, 10 or 14 of L-Asp codons (6 L-Asp, 5′-GACGATGACG ACGAT GAT-3′: 10 L-Asp, 5′-GACGA TGACG ACGATGATGACGACG ACGAC-3′: 14 L-Asp, 5′-GACGATGACG ACGAT GATGACGACGACGACGATGATGATG AT-3′) was introduced additionally at the C-terminus after c.1041G of Met347 between the spacer (5′-ACCGGTGAAG CAGAGGCC-3′) and a termination codon. The esRAGE tagged with a stretch of 6, 10 and 14 of L-Asp were named D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE, respectively.
For preparation of the first-strand cDNA, reverse transcriptase reaction was performed by using human lung total RNA. To amplify human esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE, polymerase chain reactions were carried out with the following primers: esRAGE forward 5′-ctcgagCCAGGACCC TGGAA GGAAGCAGGA-3′ and reverse 5′-tctagaTTACATGTGTTGGGGGCTA TCTTC-3′: D 6 -esRAGE, forward 5′-ctcgagCCAGGACCCTGGAAGGAAG CAGGA-3′ and reverse 5′-tctagattaatcatc gtcgtcatcgtcggcctctgcttcaccggtCATGT GTTGGGGGCTATCTTC-3′: D 10 -esRAGE, forward 5′-ctcgagCCAGGACCCTGGAA GGAAGCAGGA-3′ and reverse 5′-tctag attagtcgtcgtcgtcatcatcgtcgtcatcgtcggcctc tgcttcaccggtCATGTGTTGGGGGCTATC TTC-3′: D 14 -esRAGE, forward 5′-ctcgagCCAG GACCCTGGAAGGAAG CAGGA-3′ and reverse 5′-tctagattaatcatc atcatcgtcgtcgtcgtcatcatcgtcgtcatcgtcggcc tctgcttcaccggtCATGTGTTGGGGGCTA TCTTC-3′. The nucleotide sequences compatible with 6, 10 or 14 L-Asp were added to the reverse primers used here. The amplified cDNAs were cloned and sequenced. The cDNAs were then transferred into XhoI-XbaI cloning sites of mammalian expression vector pcDNA3.1 (+).
The esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE cDNAs subcloned in pcDNA3.1 (+) were then transfected into Chinese hamster ovary (CHO-K1) cells with Lipofectamine 2000 according to the manufacturer's instruction. Selection of colonies was carried out in growth medium with DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), plus 400 μg/mL G418 for 10-12 d. Individual clones were picked, grown to confluency and analyzed for protein expression by Western blot analysis in the medium as described below. The highest-producing clone was grown in collection medium with EX-CELL ® 325 PF CHO Serum-Free Medium for CHO Cells (protein free) and 10% heatinactivated FBS. When the cells reached confluency, the cells were rinsed with PBS and fed with collection medium without FBS to collect protein for further experiments.
Purification of Recombinant Proteins
The esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE proteins were purified by a three-step column procedure. To determine the desired protein-containing fractions in each step, the eluted fractions were analyzed by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by coomassie brilliant blue (CBB) staining. Unless stated otherwise, all steps were performed at 4°C.
Step 1. The medium containing each of the untagged and acidic oligopeptidetagged esRAGE protein was filtered through a 0.2-μm filter and then dialyzed against 25 mmol/L Tris buffer (pH 7.5) by using a Vivacell 70 centrifugal filter device.
Step 2. The dialyzed medium was applied to a column of DEAE-Sepharose equilibrated with 25 mmol/L Tris buffer (pH7.5). The column was first washed with 25 mmol/L Tris buffer (pH 7.5), and then the protein was eluted with 0-0.8 mol/L NaCl in a linear gradient.
Step 3. The eluted fractions containing the desired protein were pooled and dialyzed against 25 mmol/L Tris buffer (pH 7.5) by using a Vivaspin 15 centrifugal filter device.
Step 4. The dialyzed fractions were applied to a column of Heparin Sepharose equilibrated with 25 mmol/L Tris buffer (pH 7.5). The column was washed with 25 mmol/L Tris buffer (pH 7.5), and then the protein was eluted with 0-1.0 mol/L NaCl in a linear gradient.
Step 5. The eluted fractions containing the desired protein were pooled and dialyzed against phosphate-buffered saline (PBS) (pH 7.4) by using a Vivaspin 15 centrifugal filter device. The dialyzed fractions were then concentrated for step 6.
Step 6. The concentrated fractions were applied to a column of Sephacryl S-300-HR equilibrated with PBS. The protein was eluted with PBS.
Step 7. The eluted fractions containing the desired protein were pooled and concentrated after removal of endotoxin by using Detoxi-gel endotoxin removal gel. The concentrated fractions were stored at -80°C until use.
Western Blot Analysis
An analyte was subjected to SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was probed with primary anti-RAGE antibody, followed by incubation with horseradish peroxidase-conjugated antirabbit IgG as a secondary antibody. Blots were developed with an ECL Plus kit and scanned using Typhoon 9410 (GE Healthcare).
Hydroxyapatite-Binding Assay
HA beads were suspended in 50 mmol/L Tris-buffered saline, pH 7.4, at a concentration of 100 μg/100 μL. The purified esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE were mixed with the HA suspension at final concentrations of 10, 20 and 40 μg/mL. The mixtures were agitated at 37°C for 1 h, followed by centrifugation at 12,000g for 5 min to cap- Figure 2 . Biodistribution of fluorescence-labeled esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE to bone. The fluorescence-labeled proteins were injected into mice via the tail vein at a dose of 1 mg/kg body weight. At the indicated time points, the legs, liver and kidney were dissected and sectioned. The sections were observed under a confocal laser scanning microscope to evaluate the distribution of each esRAGE at the femoral epiphysis (A), metaphysis (B), liver (C) and kidney (D). Untagged and tagged esRAGEs were distributed in bone marrow but not in articular cartilage or in growth plate. Only the tagged esRAGEs were additionally distributed and retained in the mineralized region. AC, articular cartilage; GP, growth plate; scale bar = 100 μm.
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ture the esRAGE-bound HA beads. The supernatants were analyzed by Western blot analysis to determine the amount of unbound esRAGE. The intensity of immunoreactive blots was quantified by using ImageQuant TL software (GE Healthcare). The concentration of untagged or acidic oligopeptide-tagged es-RAGE in the supernatant was estimated from the separately established calibration curve containing the corresponding untagged and tagged esRAGEs in the range from 1.25 to 10 μg/mL. The amount of esRAGE bound to the HA beads was calculated by subtracting the amount of unbound protein from the total amount of esRAGE added to each tube. The dissociation constant (K d ) was determined from double-reciprocal plots.
Tissue Distribution of Untagged and Acidic Oligopeptide-Tagged esRAGE
A total of 1 mg/mL esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE were respectively labeled with Alexa Fluor 488 Protein Labeling Kit following the manufacturer's instructions. The Alexa-labeled esRAGE was injected into DBA/1J mice via the tail vein at a dose of 1 mg/kg body weight. Mice were killed at 6, 24, 72, 168 and 336 h after a single infusion, and legs, liver and kidney were dissected. The tissues were immersion-fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned. Fluorescence images were taken with a confocal laser scanning microscope (LSM 510; Carl Zeiss, Jena, Germany).
Assay for HMGB1 Binding to esRAGE and D 6 -esRAGE
According to the results of tissue distribution study, significant difference among acidic oligopeptide-tagged esRAGEs was not observed. Therefore, HMGB1 binding assay was performed for esRAGE and D 6 -esRAGE. Nickel affinity gel was suspended in PBS containing 4 mmol/L imidazole at a final concentration of 10 v/v%. A total of 5 μg His-tagged HMGB1 was added into the nickel affinity gel suspension. The purified esRAGE and D 6 -esRAGE were respectively mixed with the suspension and agitated at 37°C for 30 min, in which gel complexes composed of nickel affinity gel, His-tagged HMGB1 and es-RAGE or D 6 -esRAGE were allowed to form. The mixtures were centrifuged at 6,000g for 1 min to capture the gel complexes, and the gel complexes were washed three times with PBS containing 4 mmol/L imidazole. The gel complexes were agitated in PBS containing 250 mmol/L imidazole for 5 min to elute the esRAGE and D 6 -esRAGE from the gel complexes. After centrifugation at 6,000g for 1 min, the supernatants were analyzed by Western blot analysis to determine esRAGE and D 6 -esRAGE bound to His-tagged HMGB1.
Mouse Monocyte/Macrophage Cell Culture
According to the results of the tissue distribution study, a significant difference between acidic oligopeptide-tagged esRAGEs was not observed. Therefore, esRAGE and D 6 -esRAGE were used to test the effect on TNF-α production into cell culture medium. RAW264.7 cells were suspended in DMEM supplemented with 10% heat-inactivated FBS and seeded at 2 × 10 4 cells/well in a 96-well plate. At 24 h after the seeding, the cells were treated with the indicated concentration of HMGB1 in the presence or absence of esRAGE and D 6 -esRAGE. The cell culture medium was collected with the indicated time intervals after the HMGB1 treatment, and level of TNF-α in the medium was determined by using the ELISA kit. 
Murine Model of Bovine Collagen Type II-Induced Arthritis
Six-week-old DBA/1J mice were housed in a room maintained at 24.5 ± 0.5°C on a 12:12-h light-dark cycle. They were allowed to acclimate for 1 wk before the start of experiments and free access to food and water. On d 0, the mice weighing 20-30 g were treated at the base of the tail intradermally with 150 μg bovine collagen type II dissolved in 0.1 mol/L acetic acid and emulsified in CFA. On d 21, the mice were challenged by subcutaneous injection of 150 μg bovine collagen type II in IFA (32, 33) . At 14 d after primary immunization, the mice were treated with esRAGE (1.0 mg/kg per week) or D 6 -esRAGE (1.0 mg/kg per week) intraperitoneally. Vehicle treatment (control) consisted of 100 μL PBS. Treatment was continued weekly in a total of three weekly injections, and mice were killed on d 34 after primary immunization. Arthritis was evaluated semiquantitatively by clinical and histopathological scoring in a blinded manner.
Clinical severity of arthritis was characterized by palpation and observations of joint properties and inflammation of surrounding tissues in each limb. The arthritis was graded on a scale of 0-3, using the previously published scoring system (34): 0 = normal, 1 = slight swelling and/or erythema of the fingers, 2 = pronounced edematous swelling and 3 = joint rigidity with edematous swelling or joint ankylosis. Scores of 1 and 2 mainly reflect reversible edematous inflammation, but a score of 3 reflects irreversible components such as established joint ankylosis. All four limbs were investigated, providing a maximum score of 12 per mouse as a cumulative grade.
Histopathological severity of arthritis was characterized by synovial lesion, cartilage destruction and bone destruction on hematoxylin and eosin (H&E)-stained sections and Safranin O-stained sections of knee joints. Severity of arthritis was assessed in a blinded manner by two independent investigators on a scale of 0-3, by using the following scoring system (35): synovial lesions: 0 = no lesions, 1 = mild effect, 2 = moderate effect/proliferation, and 3 = severe lesions with destruction; cartilage destruction: 0 = none, 1 = mild destruction of superficial cartilage, 2 = moderate destruction, and 3 = severe destruction with loss or complete fragmentation of cartilage; bone destruction: 0 = none, 1 = mild destruction of subchondral bone, 2 = moderate destruction, and 3 = severe destruction with loss of large areas of bone.
Statistical Analysis
Statistical analysis was performed using one-way analysis of variance followed by the Tukey-Kramer post hoc test. Differences were considered to be significant at P < 0.05.
RESULTS
Characterization of Untagged and Acidic Oligopeptide-Tagged esRAGEs
Untagged esRAGE was endogenously truncated at the C-terminus, which is involved in membrane penetration, and D 1 9 : 1 8 3 -1 9 4 , 2 0 1 3 Figure 4 . HMGB1-induced TNF-α secretion in RAW264.7 cells and blockade of TNF-α secretion by esRAGE and D 6 -esRAGE. (A) RAW264.7 cells were stimulated with the indicated concentration of HMGB1, and ELISA was used to measure the level of TNF-α secreted into the conditioned medium. TNF-α was secreted in a concentration-dependent manner for 24 h after stimulation with HMGB1, and TNF-α level peaked at 6 h and then tended to decrease. Each point with a bar represents the mean ± SD of three experiments. (B) RAW264.7 cells were treated with the indicated concentration of esRAGE or D 6 -esRAGE for 1 h, and the cells were then treated with 3 μg/mL HMGB1 for 6 h, followed by measurement of TNF-α level in the conditioned medium. Secretion of TNF-α was significantly inhibited by esRAGE or D 6 -esRAGE at a concentration of 3 μg/mL. Each column with a bar represents the mean ± SD of three experiments. **Significantly different from HMGB1-untreated control at P < 0.01.
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Significantly different from HMGB1-treated control at P < 0.05.
was accordingly secreted into the culture medium when stably expressed in CHO-K1 cells. The acidic oligopeptide-tagged esRAGEs (D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE), in which a stretch of acidic oligopeptide was introduced at C-terminus of esRAGE, were secreted into the culture medium as well. The secreted amounts of esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE into the culture medium were 4.26, 5.93, 2.93 and 2.97 mg, respectively, per liter of the medium in 24 h. Their purification yields were 19.2, 32.6, 33.4 and 30.1%, respectively. Since the ligand-binding site of esRAGE locates on V-region close to N-terminus, the acidic oligopeptide stretch was tagged into C-terminus to avoid influence for ligand binding. When the purified esRAGE was subjected to SDS-PAGE under reducing conditions followed by silver staining and CBB staining, two protein bands with molecular mass of approximately 49 and 52 kDa were detected ( Figure 1A ). Silver staining was less sensitive than CBB staining for the detection of esRAGE. The purified esRAGE was also analyzed by Western blot by using polyclonal antibody against RAGE. The resultant immunoreactive two protein bands showed the same molecular mass as those of CBB staining (data not shown). The deduced increase in molecular mass associated with the stretch of acidic oligopeptide and TGEAEA spacer, for which the nucleotide sequence (5′-accggtgaagcagaggcc-3′) was introduced to create an AgeI cleavage site for cloning purpose, was observed with D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE ( Figure 1A) . esRAGE has two potential N-glycosylation sites (20) . We examined whether the two protein bands have this type of modification and are derived from variants of N-linked oligosaccharides by using PNGase F, which specifically cleaves off oligosaccharides attached to asparagine residues. When the purified untagged es-RAGE was treated with PNGase F, two protein bands with molecular masses of approximately 49 and 52 kDa disappeared, and one new band appeared at approximately 46 kDa, indicating that the untagged esRAGE was modified with two major variants of N-linked oligosaccharides ( Figure 1A ). The tagged esRAGE showed the same trend as the untagged esRAGE.
Because the action of acidic oligopeptide as a bone-targeting carrier attributes to binding affinity to HA, we examined the binding affinity of the untagged and tagged esRAGEs to HA in vitro. The binding parameter, K d , of tagged esRAGEs was approximately 20-fold lower than that of untagged RAGE (esRAGE, 47.8 μg/mL; D 6 -esRAGE, 2.6 μg/mL; D 10 -esRAGE, 3.0 μg/mL; D 14 -esRAGE, 1.6 μg/mL), meaning the affinity of tagged esRAGEs to HA was greater than that of untagged esRAGE. However, no significant difference was observed between the tagged esRAGEs forms ( Figure 1B) .
Biodistribution of Untagged and Acidic Oligopeptide-Tagged esRAGE
The biodistribution of the untagged and tagged esRAGEs was evaluated after a single injection of fluorescence-labeled esRAGE, D 6 -esRAGE, D 10 -esRAGE and D 14 -esRAGE at a dose of 1 mg/kg. Figure 2 shows the histological pictures of biodistribution of these esRAGEs at femoral epiphysis and metaphysis at 6, 24, 72, 168 and 336 h after a single intravenous injection. At 6 h, the untagged and tagged esRAGEs were equally distributed in bone marrow but were detected neither in articular cartilage nor in growth plate. However, the tagged esRAGEs were distributed to the mineralized region. At 72 h, the untagged esRAGE almost disappeared from the bone marrow, while the tagged esRAGEs were retained in the bone marrow and mineralized region. Moreover, the tagged esRAGEs were detectable until 168 h, especially at the mineralized region, and almost disappeared from the mineralized region at 336 h. The difference between the tagged esRAGEs forms was observed only at 168 h; D 10 -esRAGE and D 14 -esRAGE showed a slightly higher retention than D 6 -esRAGE at the mineralized region of the epiphysis. The distribution of untagged and tagged esRAGEs in liver and kidney was also evaluated. In liver, the distribution was widespread D 1 9 : 1 8 3 -1 9 4 , 2 0 1 3 | T A K A H A S H I E T A L . | 1 8 9 Figure 5. Suppressive effects of esRAGE and D 6 -esRAGE on inflammation in DBA/1J mice immunized with bovine collagen type II. At the indicated time points after primary immunization with bovine collagen type II, clinical scoring was performed by blinded observers. Administration of esRAGE and D 6 -esRAGE started on d 14 after the immunization when mice initially developed the sign of arthritis such as paw swelling. Each esRAGE and D 6 -esRAGE was intraperitoneally administered at a dose of 1 mg/kg per week. esRAGE ameliorated the increase in clinical score, while D 6 -esRAGE showed more significant reduction in clinical score than esRAGE from d 27 after primary immunization onward. Each point with a bar represents the mean ± standard error of the mean (SEM) of six mice. *Significantly different from vehicle-treated immunized mice (control) at P < 0.05. **Significantly different from vehicle-treated immunized mice (control) at P < 0.01. throughout the liver, including hepatocytes and sinus-lining cells. The distribution patterns in the liver were comparable between the untagged and tagged esRAGEs ( Figure 2C ). In kidney, no significant differences were also observed between the untagged and tagged esRAGEs ( Figure 2D) . At 336 h, the untagged and tagged esRAGEs were undetectable in liver and kidney (data not shown). A significant difference between acidic oligopeptide-tagged esRAGEs was not observed in the biodistribution. In addition, it is likely that a longer stretch of acidic oligopeptide affects physiological properties, except for biodistribution of esRAGE, because Nishioka et al. (27) demonstrated that the longer stretch of acidic oligopeptide more largely changed the N-linked oligosaccharides structure of glycoprotein. The ligand-binding V-domain of RAGE contains two potential N-glycosylation sites, and the N-linked oligosaccharides on RAGE are suggested to mediate the interaction with its ligands (20, 21) . It was predicted that the longer stretches, D 10 and D 14 , tagged into esRAGE may affect the binding affinity to its ligands. Taken together, we decided to use D 6 -esRAGE for further experiments.
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HMGB1-Binding Affinity of esRAGE and D 6 -esRAGE
We examined the binding affinity of esRAGE and D 6 -esRAGE to HMGB1, which is one of the endogenous ligands for RAGE. Each purified esRAGE and D 6 -esRAGE was incubated with the Histagged HMGB1 immobilized to nickelaffinity gel. Figure 3 shows that esRAGE bound to HMGB1 in a concentrationdependent manner consistent with the previous study (36) . D 6 -esRAGE showed the same trend in binding affinity to HMGB1 as that of esRAGE. It is reasonable that the ability of D 6 -esRAGE to bind to HMGB1 ligand was comparable to that of esRAGE, since the site to engage HMGB1 ligand resides in the N-terminal V domain, which both es-RAGE and D 6 -esRAGE possess. To assess the histopathological severity of arthritis focusing on synovial hyperplasia, cartilage destruction and bone destruction, histopathological scoring was performed in a blinded manner. D 6 -esRAGE provided an impact to reduce the histopathological scores on synovial lesion (disappearance of hyperplasia), cartilage destruction (smooth surface of organized articular cartilage) and bone destruction, whereas esRAGE did not show any significant preventive effect on histopathological abnormalities. Each column with a bar represents the mean ± SEM of six mice. *Significantly different from vehicle-treated immunized mice (control) at P < 0.05. AC, articular cartilage; JC, joint cavity; P, pannus; S, synovium; scale bar = 100 μm.
Blockade of HMGB1-Induced TNF-α Secretion by esRAGE and D 6 -esRAGE
The previous study demonstrated that HMGB1 interacts with cell surface TLR-2 and TLR-4 on RAW264.7 cells and activates downstream signals (37) . To clarify the potential ability of esRAGE and D 6 -esRAGE to function as a decoy receptor, we investigated whether esRAGE and D 6 -esRAGE could inhibit the HMGB1-induced TNF-α secretion by RAW264.7 cells. RAW264.7 cells were stimulated with HMGB1, and the level of TNF-α secreted into conditioned medium was measured by ELISA. The peak TNF-α level after stimulation with HMGB1 occurred at 6 h and tended to decrease after 24 h. TNF-α was secreted in a concentration-dependent manner at each time point after stimulation with HMGB1 ( Figure 4A ). In the presence of esRAGE or D 6 -esRAGE, TNF-α secretion induced by 3 μg/mL HMGB1 was downregulated in a concentration-dependent manner and significantly inhibited at a concentration of 3 μg/mL esRAGE or D 6 -esRAGE ( Figure 4B ).
Therapeutic Effects on Murine
Collagen-Induced Arthritis by esRAGE and D 6 -esRAGE DBA/1J mice were immunized with bovine type II collagen in CFA and then boosted with bovine type II collagen in IFA on d 21 after primary immunization. Vehicle (PBS), esRAGE (1.0 mg/kg) or D 6 -esRAGE (1.0 mg/kg) was administered to the immunized mice intraperitoneally once a week from d 14 after primary immunization, when the clinical signs of collagen-induced arthritis (CIA) first appeared. To determine and compare the anti-arthritic effect of esRAGE and D 6 -esRAGE, clinical score was assessed three times a week. After 2-3 wks after the first injection of bovine type II collagen, mice developed paw swelling. Vehicle-treated immunized mice (control) displayed significant increase in the clinical arthritis score when compared with nonimmunized mice (sham), but arthritis progression and severity were prevented in the esRAGE-and D 6 -esRAGE-treated immunized mice. The preventive effect was observed even in esRAGE-treated mice, although D 6 -esRAGE-treated mice showed further lower clinical scores at all time points, suggesting the more clinical improvement compared with esRAGE-treated mice ( Figure 5 ).
In histopathological evaluation by H&E staining and Safranin O staining, the knee joints of the untreated control mice evidenced notable synovial hyperplasia, depletion of proteoglycan and chondrocytes in articular cartilage, and bone destructions ( Figure 6A) . Treatment of D 6 -esRAGE markedly attenuated these histopathological findings (P < 0.05). However, esRAGE-treated mice did not show any significant preventive effect on histopathological abnormalities (synovial lesion, P = 0.7405; cartilage destruction, P = 0.6100; bone destruction, P = 0.9299) ( Figure 6B ).
At the end of the experimental period, the levels of TNF-α, IL-1 and IL-6 in plasma were significantly elevated in untreated control CIA mice compared with sham mice (P < 0.001) (Figure 7 ). Treatment with esRAGE suppressed the elevation of levels of TNF-α and IL-1 observed in untreated CIA mice (P < 0.05), but reduction of IL-6 level was not significant in esRAGE-treated mice (P = 0.0959). Meanwhile, D 6 -esRAGE reduced the levels of all these proinflammatory cytokines (P < 0.05), including IL-6, and production of IL-1 and IL-6 was more reduced when compared with esRAGE.
DISCUSSION
We have demonstrated here that the current approach using D 6 -esRAGE ame- liorates the characteristic pathological features on murine CIA. In the pathological process of RA, HMGB1 appears to be a key signal transduction ligand of TLR-2, TLR-4 and RAGE and is implicated in amplification of proinflammatory responses. Accumulation of HMGB1 in synovial fluids and serum of subjects with RA has been correlated with disease severity (9) . These findings suggested that neutralization of the interactions between HMGB1 and the cell surface receptors via a soluble decoy receptor, sRAGE, is a potential therapeutic agent for RA. Hofmann et al. (38) reported that sRAGE administration ameliorates the clinical and histopathological features in murine CIA. However, the dose of administered sRAGE was substantially higher (daily 100 μg/mouse equivalent to weekly 35 mg/kg) compared with other biologics, implying that biological activity of sRAGE is lower and/or that biodistribution of sRAGE is unfavorable for treatment for CIA. Indeed, we observed that a much lower dose of esRAGE (weekly 1 mg/kg) showed little effectiveness on CIA. To resolve this issue and to prove the therapeutic effect of sRAGE, we hypothesized that drug delivery system to bone could be a valuable additive approach. Thus, we attempted to deliver esRAGE to bone by using a bone-targeting system.
It is known that the ligand-binding V-domain of RAGE contains two potential N-glycosylation sites, and PNGase F treatment reduces its molecular mass, indicating that the RAGE is a glycoprotein. In this study, both untagged and acidic oligopeptide-tagged esRAGEs expressed by CHO-K1 cells were highly glycosylated and were modified with two major variants of N-linked oligosaccharides. Both variants of N-linked oligosaccharides on esRAGE and D 6 -esRAGE showed a similar binding affinity to HMGB1 ligand. This finding implies that both variants function as a decoy receptor for HMGB1; therefore, we used both variants for further experiments. Recent studies revealed that the S100 protein levels in the serum and synovial fluids correlate with the arthritis severity as well as HMGB1 (39, 40) . S100 proteins bind to RAGE and TLR-4 and activate their downstream signals, resulting in increased production of matrix-degrading enzymes, such as matrix metalloproteinases, which are involved in cartilage degradation and progression of RA (41) . It is likely that highly glycosylated es-RAGE and D 6 -esRAGE have binding affinity to S100 proteins, since RAGE enriched for N-linked oligosaccharides shows higher binding affinity to S100 proteins as well as HMGB1 (42, 43) . Consistently, the binding affinity of diverse ligands such as HMGB1 and S100 proteins to RAGE decreases when RAGE is deglycosylated, indicating that the N-linked oligosaccharides on RAGE mediate the interaction with its ligands (42) (43) (44) . However, structural influence of N-linked oligosaccharides on RAGE for ligand binding is not completely understood. Further analyses are needed to confirm that esRAGE and D 6 -esRAGE bind to ligands other than HMGB1.
A question addressed was whether administered D 6 -esRAGE could be delivered to relevant tissues. Pathological lesions in CIA appear not only in bone but also in synovial tissue, which does not contain HA. Consistent with the previous studies (27, 28) , acidic oligopeptide-tagged esRAGEs, including D 6 -esRAGE, were localized to a mineralized region in bone, where they were retained for over 1 week. The principle of bone-targeting by using an acidic oligopeptide is based on the affinity between negatively charged acidic oligopeptide and positively charged calcium in HA. Retention of D 6 -esRAGE was not observed in synovial tissue. In addition, D 6 -esRAGE was not distributed to avascular regions, such as articular cartilage and growth plate. Despite these facts, why did D 6 -esRAGE significantly attenuate the synovial hyperplasia in murine CIA while esRAGE showed little improvement? One can speculate that the prolonged retention of D 6 -esRAGE in bone provides a great Figure 8 . Proposed hypothesis of mechanism of D 6 -esRAGE on RA pathogenesis. TNFR, TNF receptor; MMPs, matrix metalloproteinases.
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